- Market Capitalization, $K 110,212,880
- Shares Outstanding, K 2,496,328
- Annual Sales, $ 42,135 M
- Annual Income, $ 5,101 M
- 60-Month Beta 0.53
- Price/Sales 2.69
- Price/Cash Flow 8.41
- Price/Book 1.58
|Period||Period Low||Period High||Performance|
| || |
+1.56 (+3.69%)since 05/24/19
| || |
-0.42 (-0.95%)since 03/22/19
| || |
+3.84 (+9.60%)since 06/22/18
Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.
BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.
Alphabet's (GOOGL) Verily joins hands with Novartis, Sanofi, Otsuka and Pfizer to revolutionize the clinical trial methods.
Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
|Intl Devd Markets Ishares Core MSCI ETF|
|USD Bond Market Total Ishares Core ETF|
|Intl Momentum Factor Ishares Edge MSCI ETF|
|Exponential Technologies Ishares ETF|
|Invst Grade Corp Bond Ishares Iboxx $ ETF|